The SBC Catalyser Programme
Do you have a winning commercialisation strategy?
The 8-week Catalyser programme helps therapeutics/techbio companies refine their commercialization strategy through a journey involving 12 meso-economic vectors as described by the Triple Chasm model. At the end of the 14 sessions (3 in-person and 11 videocalls) each company gains:
- a clear execution plan
- access to experts, potential partners and investors
Each session is focused on one of the 12 Triple Chasm vectors and includes:
- review of each startup strategy on previous vector
- panel discussion with 3-4 industry experts to help understand real world scenarios and trend
WHY you should apply
The SBC Catalyser programme provides:
- A comprehensive commercial strategy to go from prototype to commercially viable product
- A clear execution plan to translate the strategy into action
- Support to understand and embed digital and data technologies into your workflow
- A strategically aware leadership team, able to evolve their commercialisation strategies in response to changes in markets and technologies
- An extended network across the SBC ecosystem; enabling teams to talk to key customers, partners, suppliers and investors
- An enhanced company profile
- Improved chances of getting the right funding, investment and lab space
HOW to achieve your goals
The programme includes:
- Strategy profiling using a range of specialist tools
- Commercialisation strategy development workshops focused on the 12 vectors of growth including: positioning, funding, market, IP management, manufacturing, distribution, human capital management
- 14 sessions over 8 weeks, with panel discussions involving Benevolent AI, Cambridge Innovation Capital, Start Codon, CGT Catapult, Eagle Genomics, o2h, Department of Business and Trade, IQVIA, Redx Pharma, Multiply AI, Virtarka and more.
- Being part of the SBC campus and its community including GSK, the Cell and Gene Therapy Catapult (CGTC) and over 40 other growing therapeutics companies
- Access to a world class team of mentors and experts, investors and partners
- Demo Day and Partnering opportunities
WHO you are
- You are developing therapeutic innovations
- You have already built a proof of concept and you are planning to create the first commercially viable product
- You have integrated digital and data technologies (ie ML/AI) in your R&D workflow, or you are planning to integrate them
- You have an existing presence in the UK, or you are planning to establish a presence in the UK
- You have an ambitious leadership team of at least 2-3 that can commit to full participation in the programme, including in-person activities at SBC on the first day (23rd May) and the last 2 days (13-14th July).
WHO we are
- Campus of 40+ therapeutics companies and largest cluster of CGT companies in Europe
- Companies based at SBC have raised more than £2.9bn since SBC's birth in 2012
- Our campus also includes GSK, LifeArc, CGTC and Cytiva
- We provide lab-space, office-space and business development support to our occupiers
- Our Lab Hotel provides free lab-space for 6 months to 4 selected early-stage companies
Read our Economic Impact Assessment report for more information.
Delivered in Collaboration with:
Click here for information on the 2021 "DATA Programme"
-
Consone AI develops a platform to empower user decision making by successfully predicting effects and viability of new drugs. The ... -
Genenet Technology (UK) Ltd integrates state-of-art deep learning neural networks into the gene circuit design. This unleashes the potential of ... -
Kuano create superior oncology medicines by adding quantum detail to structure-based drug discovery. The technology fuses state of the art simulation, ... -
Neobe is developing a platform for the engineering of programmable live biotherapeutics, which can colonize solid tumours and remodel their ... -
Pentabind use Generative AI to design aptamers that can bind to transcription factors unlike traditional drugs. They have built the ... -
Plurify develop innovative solutions for efficiently differentiating PSCs to highly pure populations of transplantable cells. This approach will generate numerous ... -
RS & RS Scientific develop personalized gene therapies for lung cancer with AI-powered platform. -
We passionately join cancer patients in their fight for effective, safe, non-toxic cancer treatments that increase quality of life and ... -
Turing Biosystems develop a reasoning AI software platform to allow companies and clinicians optimize therapies by integrating, analyzing, and interpreting ... -
VasoDynamics is a UK-based pharmaceutical development company with a pipeline of drugs in development to address the side-effects associated with ...
Be part of SBC Catalyser Programme!
Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.
Contact MarcoCopyright © 2023 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.